The ultimate goal of our research is to reduce the incidence of Parkinson's disease (PD) by eliminating causal factors or delaying the age at onset. PD is a progressive movement disorder that affects 1-2% of the population over the age of 60, and many who are younger. Millions of individuals suffer from PD world-wide. Symptomatic treatment is available, but progression of disease and complications of therapy cause increasing disability. Effective intervention to reduce the incidence and delay the onset will require understanding the causes of PD and factors that modulate its expression. Both genes and environment are thought to play important roles in the pathogenesis of PD.
The aims of this study are to identify genes that affect PD susceptibility and age at onset, and to study the interaction of these genes with two environmental factors that are inversely associated with PD risk;namely, smoking and coffee. Identifying susceptibility genes will provide clues to the causes of PD and may suggest new strategies for prevention. Genetic screening may be developed to identify at risk individuals for early intervention. Identifying genes that modulate age at onset will provide the necessary insight for developing ways to delay onset of symptoms. Studying the genetics of PD in the context of environmental factors will boost the power of the study and may help gain additional clues to disease pathogenesis. To achieve these aims we will perform a genome-wide association study with 2000 PD patients and 2000 control subjects, using genotyping technologies that allow analysis of single nucleotide polymorphisms and copy number variants. We will test each marker for main effect, gene x gene and gene x environment interactions, affecting risk or age at onset. The most promising findings will be replicated in independent data sets. Finally, since PD associated markers may only be proxies;fine mapping will be performed to pinpoint the actual PD genes. The infrastructure for this study is in place, including over 2000 well-characterized PD patients and 2000 controls, high quality DNA banked on all subjects, data on environmental exposures, and a multi-institutional interdisciplinary team of investigators with expertise in neurology, molecular genetics, statistical genetics, epidemiology, molecular biology and neuropathology. During the proposed study, we will continue to maintain this infrastructure, which was founded and supported by this grant since 1998.
This study aims to identify genes that affect the risk or age at onset of Parkinson's disease (PD). Once these genes are identified, the information can be used to develop strategies for early detection and prevention.
|Hill-Burns, Erin M; Debelius, Justine W; Morton, James T et al. (2017) Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord 32:739-749|
|Barrett, Matthew J; Koeppel, Alexander F; Flanigan, Joseph L et al. (2016) Investigation of Genetic Variants Associated with Alzheimer Disease in Parkinson Disease Cognition. J Parkinsons Dis 6:119-24|
|Hill-Burns, Erin M; Ross, Owen A; Wissemann, William T et al. (2016) Identification of genetic modifiers of age-at-onset for familial Parkinson's disease. Hum Mol Genet 25:3849-3862|
|Sharp, Madeleine E; Caccappolo, Elise; Mejia-Santana, Helen et al. (2015) The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord 30:278-83|
|Nalls, Mike A; Pankratz, Nathan; Lill, Christina M et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46:989-93|
|Hill-Burns, Erin M; Wissemann, William T; Hamza, Taye H et al. (2014) Identification of a novel Parkinson's disease locus via stratified genome-wide association study. BMC Genomics 15:118|
|Hamza, Taye H; Hill-Burns, Erin M; Scott, William K et al. (2014) Glutamate receptor gene GRIN2A, coffee, and Parkinson disease. PLoS Genet 10:e1004774|
|Alcalay, Roy N; Caccappolo, Elise; Mejia-Santana, Helen et al. (2014) Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 71:62-7|
|Hall, Taryn O; Wan, Jia Y; Mata, Ignacio F et al. (2013) Risk prediction for complex diseases: application to Parkinson disease. Genet Med 15:361-7|
|Hill-Burns, E M; Singh, N; Ganguly, P et al. (2013) A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. Pharmacogenomics J 13:530-7|
Showing the most recent 10 out of 53 publications